Skip to content

Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy

A Randomised Control Trial Comparing the Effectiveness of Yellow 577 nm Laser to Conventional Green 532 nm Laser for Proliferative Diabetic Retinopathy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01044875
Acronym
UMPDR
Enrollment
120
Registered
2010-01-08
Start date
2009-09-30
Completion date
2011-10-31
Last updated
2010-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proliferative Diabetic Retinopathy

Keywords

Diabetic retinopathy, Laser treatment, Complications, Laser wavelength

Brief summary

The purpose of this study is to measure effectiveness of yellow 577 nm laser compared to conventional green laser 532 nm for diabetic retinopathy in terms of number of treatment sessions required and visual acuity outcome. The study also compares pain score of patients receiving laser treatment and side effects of laser treatment.

Detailed description

Diabetes mellitus (DM) is a major medical problem throughout the world. The most common and potentially most blinding of these complications is proliferative diabetic retinopathy (PDR). Panretinal photocoagulation is established as the gold standard of treatment, supported by the data of the Diabetic Retinopathy Study (DRS).This study found that laser treatment reduced the rate of severe visual loss by 50%. Currently the green 532nm laser is the most common wavelength used. However, this conventional green laser has some complications such as pain, vitreous haemorrhage, choroidal effusion and visual field loss. Due to the complication of conventional lasers, the yellow laser (577 nm)with peak absorption of oxyhemoglobin and good absorption of melanin is postulated to be more effective at producing retinal laser burns with a lower power and less pain compared to the green laser.

Interventions

PROCEDUREPan retinal photocoagulation laser treatment

Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.

Sponsors

University of Malaya
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient more than 18 year of age * Eyes with proliferative diabetic retinopathy requiring laser PRP * Newly diagnosed patient * Patients with no other intervention/surgeries done before the study

Exclusion criteria

* Eyes with media opacity not allowing adequate laser photocoagulation * Patients who have had previous laser photocoagulation * Patients who have had previous vitreoretinal surgery

Design outcomes

Primary

MeasureTime frame
Visual acuity measurement by logarithm of the minimum angle of resolution (logMAR)2 years

Secondary

MeasureTime frame
Patient pain score during laser procedure2 years

Countries

Malaysia

Contacts

Primary ContactThirupathy Annamalai, MBBS
thirusukan@yahoo.com+79492060

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026